DB17424InvestigationalVaccines
MVA-BN-brachyury-TRICOM vaccine is an investigational cancer vaccine. It is composed of recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human transcription factor and tumour-associated antigen (TAA) brachyury,... These immune-enhancing co-stimulatory molecules exert immunostimulatory and antineoplastic actions.
- Also known as
- MVA-BN-Brachyury · MVA-BN-Brachyury Prime Vaccine
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of MVA-BN-brachyury-TRICOM vaccine, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account